Skip to Content
About Abbott
Contact
United States | eng
Country Language
CARDIOVASCULAR
United States | eng
Country Language

CardioMEMS HF System

For pulmonary artery pressure monitoring

CardioMEMS HF System
About

Clarity in Care: Slow the progression of heart failure with early intervention using presymptomatic data

Abbott’s CardioMEMS™ HF System is the leading remote monitoring platform for both HFpEF1 and HFrEF patients clinically proven to:

  • aid physicians in preventing worsening heart failure2
  • lower mortality rates3
  • improve quality of life4

As telemedicine becomes more common, the CardioMEMS HF System is a safe, reliable way to help your patients manage their heart failure.

The CardioMEMS HF System offers you real-time notification of patient changes and simple, convenient access to secure data for proactive, personalized patient management. It also provides patients with a heightened awareness of the factors affecting their health and a powerful sense of control.

Monitoring Pulmonary Artery (PA) Pressures is Proactive and Actionable

The CardioMEMS HF System remotely monitors changes in pulmonary artery (PA) pressure, an early indicator of the onset of worsening heart failure. These early changes can often be addressed through simple adjustments to care, such as titration of medications, most often without requiring an appointment with the patient.

Traditionally, clinicians have focused on physiological markers (patient weight, blood pressure, etc.) to detect worsening heart failure. Unfortunately, these markers appear late in the time course of decompensation. Relying on them leaves little time to respond before hospitalization is necessary.

Chart showing 30 days preceding heart failure hospitalization indicating markers of heart failure moving from early changes of pulmonary artery pressure changes and autonomic adaptation changes to weight change and symptoms.

View More About Patient Selection & Assessment

The CardioMEMS HF System is the fastest growing technology to manage both HFrEF and HFpEF patients

The CardioMEMS HF System is proven through clinical trial data to reduce heart failure hospitalizations and mortality,2,3 as well as improve QOL for HFrEF and HFpEF patients.3,4,5 The presymptomatic data provided by the CardioMEMS HF System allow for proactive changes in medical therapy before heart failure symptoms appear.1 The ability to individually set patient thresholds allows physicians to personalize and optimize care and medical management for each patient.

View Clinical Trial Data

Reimbursement & Coding

Reimbursement & Coding

Manuals & Resources

Manuals & Resources

Customer Service

Customer Service

References

  1. Adamson PB, Abraham WT, Bourge RC, Costanzo MR, Hasan A, Yadav C, et al. Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. Circulation: Heart Failure. 2014;7(6):935-944.
  2. Adamson PB. Pathophysiology of the transition from chronic compensated and acute decompensated heart failure: new insights from continuous monitoring devices. Current Heart Failure Reports. 2009;6:287-292.
  3. Abraham J, et al. Association of Ambulatory Hemodynamic Monitoring with Clinical Outcomes in a Concurrent Matched Cohort Analysis. JAMA Cardiology. 2019;4(6):556-563.
  4. Abraham WT, Stevenson LW, Bourge RC, Lindenfeld JA, Bauman JG, Adamson PB, for the CHAMPION Trial Study Group. Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. The Lancet. 2016;387(10017):453-461.
  5. Angermann, C.E., Assmus, B., Anker, S.D. et al. Safety and feasibility of pulmonary artery pressure-guided heart failure therapy: rationale and design of the prospective CardioMEMS Monitoring Study for Heart Failure (MEMS-HF). Clin Res Cardiol. 107, 991–1002 (2018). https://doi.org/10.1007/s00392-018-1281-8
  6. Desai AS, Bhimaraj A, Bharmi R, et al. Ambulatory hemodynamic monitoring reduces heart failure hospitalizations in “real-world” clinical practice. J Am Coll Cardiol. 2017;69(19):2357-65.
  7. Givertz MM, Stevenson LW, Costanzo MR, et al., on behalf of the CHAMPION Trial Investigators. Pulmonary artery pressure–guided management of patients with heart failure and reduced ejection fraction. J Am Coll Cardiol. 2017;70:1875-86.

MAT-2006906 v5.0

POLICIES & ADVISORIES
HEALTHCARE PROFESSIONALS
PATIENTS & CAREGIVERS
abbott logo

CAUTION: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or online for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Illustrations are artist's representations only and should not be considered as engineering drawings or photographs.

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. ™ Indicates a trademark of the Abbott group of companies. ‡ Indicates a third party trademark, which is property of its respective owner.

© 2023 Abbott. All Rights Reserved.

MAT-1900882 v10.0